Bartosz Pomirski

Bartosz Pomirski

Auto-generated profile, based on publicly available information

Bartosz Pomirski

Faculty of Medicine, Medical University of Warsaw żwirki i wigury 61, 02-091 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
APAgata Pomirska
Agata Pomirska
BPBartosz Pomirski
Bartosz Pomirski
AWAnna Wilewska
Anna Wilewska
JBJulia Biernikiewicz
Julia Biernikiewicz
KAKonstanty Alabrudziński
Konstanty Alabrudziński
PKPaulina Kwaśniewska
Paulina Kwaśniewska
Introduction. Trigeminal neuralgia (TN) is a rare but debilitating craniofacial pain disorder characterized by sudden, severe, electric shock-like episodes affecting one or more branches of the trigeminal nerve. Despite its low prevalence, TN has a profound impact on quality of life. Accurate diagnosis and subtype classification are essential for guiding treatment. Advanced neuroimaging techniques help identify structural causes and guide therapy.Purpose. This review offers a comprehensive, evidence-based summary of current treatment strategies for TN, including pharmacological, surgical, and supportive modalities. Special attention is given to recent advances and options for patients with refractory or complex cases.Materials and Methods. This review is based on a structured analysis of peer-reviewed literature retrieved from PubMed, Google Scholar, and the Cochrane Library. Selection prioritized systematic reviews, randomized controlled trials, clinical guidelines, and high-quality cohort studies published between 2000 and 2024. Emphasis was placed on clinical relevance and methodological rigor.Conclusion. Effective management of trigeminal neuralgia demands an individualized, stepwise approach. While carbamazepine and oxcarbazepine remain first-line treatments, a significant subset of patients requires surgical or adjunctive therapies. Microvascular decompression offers the best long-term outcomes in classical TN, whereas less invasive procedures and botulinum toxin injections may benefit selected patients. Neuromodulation techniques are emerging alternatives for drug-resistant cases. Multidisciplinary care is essential for accurate diagnosis and individualized treatment.

9 December 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
JBJulia Biernikiewicz
Julia Biernikiewicz
AWAnna Wilewska
Anna Wilewska
BPBartosz Pomirski
Bartosz Pomirski
APAgata Pomirska
Agata Pomirska
MBMilena Biernikiewicz
Milena Biernikiewicz
PGPatryk Graczyk
Patryk Graczyk
IntroductionEosinophilic fasciitis (EF) is a rare inflammatory disorder marked by elevated eosinophils in tissues and blood. Patients typically present with symptoms such as skin swelling, pain, and induration, which can be mistaken for other connective tissue diseases. The pathogenesis of EF is not fully understood, though immune and autoimmune mechanisms appear to play significant roles. Diagnosis often involves biopsies, lab analyses, and imaging techniques. Current treatment mainly consists of corticosteroids, but further research is needed to assess various therapeutic strategies. Understanding EF is essential for improving patient outcomes and quality of life. Purpose The purpose of this article is to enhance knowledge of eosinophilic fasciitis by examining its pathogenesis, immune mechanisms, and diagnostic challenges, as well as evaluating current diagnostic criteria and treatments. Given the rarity and complexity of EF, the study also seeks to clarify its differentiation from similar diseases and offer insights into effective therapies for early diagnosis and improved treatment outcomes. ConclusionEF is a rare disease, and its complexity, due to diverse etiologies and variable treatment efficacy, poses significant challenges in clinical practice. In the near future, the publication of new cases and the initiation of clinical trials should contribute to the development of innovative therapeutic strategies and an effective treatment algorithm. Materials and methods: Our review is based on an analysis of material collected in 'Pubmed', 'Google Scholar' and other scientific articles using the keywords: Eosinophilic fasciitis, Shulman, fibrosis, hypergammaglobulinemia, eosinophilia.

20 December 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
KAKonstanty Alabrudziński
Konstanty Alabrudziński
AWAnna Wilewska
Anna Wilewska
BPBartosz Pomirski
Bartosz Pomirski
JBJulia Biernikiewicz
Julia Biernikiewicz
MBMilena Biernikiewicz
Milena Biernikiewicz
ADAleksandra Dach
Aleksandra Dach
The EVALI (E-cigarette or Vaping product use-Associated Lung Injury) epidemic of 2019 was a major public health challenge, attracting the attention of both the scientific community and the public. In a short period of time, thousands of cases of acute lung injuries and deaths were reported among e-cigarette users, previously unrelated to the risk, shedding new light on the safety of these devices and exposing gaps in the regulations regarding their use. This paper aims to review the literature on the EVALI epidemic, with particular emphasis on epidemiology, identification of the etiological agent, clinical presentation and treatment. Based on the collected data, the authors also analysed the possibilities of preventing similar events in the future, emphasizing regulations, health education of patients and increasing physicians' awareness of EVALI.

5 January 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
PGPatryk Graczyk
Patryk Graczyk
PKPaulina Klaudia Kwaśniewska
Paulina Klaudia Kwaśniewska
AWAnna Wilewska
Anna Wilewska
KBKinga Borowiec
Kinga Borowiec
ABAgnieszka Borowiec
Agnieszka Borowiec
APAgata Pomirska
Agata Pomirska
Introduction: Wilson disease (WD) is a genetic disorder of copper metabolism caused by ATP7B gene mutations, impairing copper excretion and leading to copper accumulation in organs. It affects children and adults, causing liver damage, cirrhosis, neuropsychiatric symptoms, and, if untreated, death. Symptoms, such as Kayser-Fleischer rings, neurological issues, and low serum ceruloplasmin levels, vary widely, complicating early diagnosis. Although rare, WD is one of the few preventable movement disorders, with treatments available to slow disease progression. Purpose: This review aims to enhance understanding and management of WD by summarizing current guidelines and offering practical recommendations for clinical practice. Material and methods: In our article, we have comprehensively discussed WD. Reviewing the latest literature, we have summarized the symptoms, etiology, diagnosis, treatment and prognosis of this disease. Discussion: Wilson disease remains a significant clinical challenge due to its heterogeneous presentation and difficulty in early diagnosis. Despite effective treatments, that can prevent disease progression, many patients experience delayed diagnosis, leading to irreversible organ damage. Advances in genetic testing and biomarkers have improved diagnostic accuracy, enabling earlier detection and better management outcomes. However, nonadherence to lifelong therapy remains a major hurdle, emphasizing the need for ongoing patient education. Emerging therapies and personalized medicine offer promise for improving outcomes and minimizing long-term complications, highlighting the need for continued research and treatment refinement.

9 December 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
AWAnna Wilewska
Anna Wilewska
BPBartosz Pomirski
Bartosz Pomirski
APAgata Pomirska
Agata Pomirska
JBJulia Biernikiewicz
Julia Biernikiewicz
MBMilena Biernikiewicz
Milena Biernikiewicz
PGPatryk Graczyk
Patryk Graczyk
Introduction and Purpose: Cerebral palsy (CP) is a prevalent neurological disorder in children, characterized by movement, muscle tone, and posture impairments. This article reviews the clinical and therapeutic management of CP, focusing on spasticity, musculoskeletal disorders, and holistic rehabilitation. It examines evidence-based interventions, including onabotulinumtoxinA, intrathecal baclofen pumps, and surgical options for orthopedic deformities. Key rehabilitation techniques such as neurodevelopmental therapies, gait training, and speech therapy are discussed to enhance motor skills and cognitive development. Additionally, the management of associated conditions like epilepsy and intellectual challenges is addressed, emphasizing psychological support for patients and families. The purpose of this article is to provide a comprehensive overview of the current state of knowledge regarding the management of cerebral palsy. Material and Methods: We utilized English databases such as PubMed, Google Scholar, Cochrane, and PubMed Central, selecting articles based on keywords like cerebral palsy, spasticity, physical therapy, and rehabilitation. State of Knowledge: Effective CP management requires a multidisciplinary approach to tackle motor impairments, spasticity, deformities, and psychosocial challenges. Therapeutic interventions, including pharmacological treatments, surgical options, and innovative rehabilitation techniques, are essential for improving mobility and quality of life. Summary: Comprehensive care for children with CP is crucial. Evidence supports combining multiple therapeutic approaches tailored to each child’s needs and involving family preferences to optimize development and well-being.

17 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
BPBartosz Pomirski
Bartosz Pomirski
AWAnna Wilewska
Anna Wilewska
APAgata Pomirska
Agata Pomirska
JBJulia Biernikiewicz
Julia Biernikiewicz
KAKonstanty Alabrudziński
Konstanty Alabrudziński
PKPaulina Kwaśniewska
Paulina Kwaśniewska
Introduction. Direct oral anticoagulants (DOACs) offer superior clinical convenience over traditional therapies. However, their use in postpartum women is heavily constrained, routinely forcing a choice between optimal venous thromboembolism (VTE) prophylaxis, and breastfeeding due to a lack of high-certainty safety data.Objective. This review synthesizes clinical data regarding DOAC excretion into human breast milk, evaluates current pharmacokinetic indices and outlines the methodological limitations hindering definitive clinical guidelines.Materials and Methods. A comprehensive literature search was conducted in the PubMed database up to June 2026 to evaluate human clinical data concerning maternal DOAC therapy and subsequent infant exposure metrics.Results. Available evidence indicates distinct profiles among DOACs. Apixaban exhibits significant accumulation in breast milk driven by active BCRP transport, yielding an unacceptable Relative Infant Dose (RID) of up to 21%. Conversely, rivaroxaban and dabigatran demonstrate promising safety margins, with RIDs substantially below the 10% safety threshold. Data regarding edoxaban remain constrained to an isolated case report.Conclusion. Contemporary literature is severely undermined by methodological vulnerabilities, including small sample sizes, lack of standardized milk fraction sampling (foremilk vs. hindmilk), and non-steady-state sampling parameters. Due to the suspension of breastfeeding during trials, investigators frequently rely on mathematical proxies like the Relative Infant Dose Daily (RIDD). To establish high-certainty guidelines, future protocols must address these flaws, utilize advanced PBPK modeling and implement long-term observational registries to evaluate infant safety.